AACR Virtual Meeting: Myeloma: Discovery to Therapy
April 26-27, 2021
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts
Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, Massachusetts
Myeloma is the second most common blood cancer diagnosis in the United States, with an estimated 32,270 new cases in 2020. Patient outcomes have improved over the last few years due to the development and FDA approval of novel therapeutics. New therapeutic options remain a priority to counter a lack of response to treatment and treatment resistance or relapse.
This virtual meeting will be the first AACR conference focused on myeloma and will discuss the genomics and epigenetics of myeloma, disease progression, and treatment options in hopes of improving clinical outcomes. Sessions will feature talks from leaders in the field and extended panel discussions.
Attendee registration includes access to all sessions presented during the live April 26-27, 2021, program and to the on-demand recordings. On-demand materials will be available for 90 days starting approximately 5-7 business days after the live program ends.
Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available
*Artwork from Chesi M et al. Monosomic loss of MIR15A/MIR16-1 Is a driver of multiple myeloma proliferation and disease progression. Blood Cancer Discov 2020;1:68–81. Read the full article here.